Engineered enteroendocrine cells secrete insulin in response to glucose and reverse hyperglycemia in diabetic mice

Jaeseok Han, Hyune Hwan Lee, Hyokjoon Kwon, Seungjin Shin, Ji Won Yoon, Hee Sook Jun

Research output: Contribution to journalArticle

25 Citations (Scopus)

Abstract

Type 1 diabetes is a metabolic disorder caused by loss of insulin-producing pancreatic β-cells. Expression of insulin in non-β-cells to create β-cell surrogates has been tried to treat type 1 diabetes. Enteroendocrine K cells have characteristics similar to pancreatic β-cells, such as a glucose-sensing system and insulin-processing proteases. In this study, we genetically engineered an enteroendocrine cell line (STC-1) to express insulin under the control of the glucose-dependent insulinotropic polypeptide promoter. We screened clones and chose one, Gi-INS-7, based on its high production of insulin. Gi-INS-7 cells expressed glucose transporter 2 (GLUT2) and glucokinase (GK) and secreted insulin in response to elevated glucose levels in vitro. To determine whether Gi-INS-7 cells can control blood glucose levels in diabetic mice, we transplanted these cells under the kidney capsule of streptozotocin (STZ)-induced diabetic mice and found that blood glucose levels became normal within 2 weeks of transplantation. In addition, glucose tolerance tests in mice that became normoglycemic after transplantation with Gi-INS-7 cells showed that exogenous glucose was cleared appropriately. These results suggest that engineered K cells may be promising surrogate β-cells for possible therapeutic use for the treatment of type 1 diabetes.

Original languageEnglish (US)
Pages (from-to)1195-1202
Number of pages8
JournalMolecular Therapy
Volume15
Issue number6
DOIs
StatePublished - Jun 2007
Externally publishedYes

Fingerprint

Enteroendocrine Cells
Hyperglycemia
Insulin
Glucose
Type 1 Diabetes Mellitus
Blood Glucose
Transplantation
Insulysin
Glucokinase
Facilitative Glucose Transport Proteins
Therapeutic Uses
Glucose Tolerance Test
Streptozocin
Capsules
Clone Cells

ASJC Scopus subject areas

  • Molecular Biology

Cite this

Engineered enteroendocrine cells secrete insulin in response to glucose and reverse hyperglycemia in diabetic mice. / Han, Jaeseok; Lee, Hyune Hwan; Kwon, Hyokjoon; Shin, Seungjin; Yoon, Ji Won; Jun, Hee Sook.

In: Molecular Therapy, Vol. 15, No. 6, 06.2007, p. 1195-1202.

Research output: Contribution to journalArticle

Han, Jaeseok ; Lee, Hyune Hwan ; Kwon, Hyokjoon ; Shin, Seungjin ; Yoon, Ji Won ; Jun, Hee Sook. / Engineered enteroendocrine cells secrete insulin in response to glucose and reverse hyperglycemia in diabetic mice. In: Molecular Therapy. 2007 ; Vol. 15, No. 6. pp. 1195-1202.
@article{fd5c858543744e589b237b469e06a7d9,
title = "Engineered enteroendocrine cells secrete insulin in response to glucose and reverse hyperglycemia in diabetic mice",
abstract = "Type 1 diabetes is a metabolic disorder caused by loss of insulin-producing pancreatic β-cells. Expression of insulin in non-β-cells to create β-cell surrogates has been tried to treat type 1 diabetes. Enteroendocrine K cells have characteristics similar to pancreatic β-cells, such as a glucose-sensing system and insulin-processing proteases. In this study, we genetically engineered an enteroendocrine cell line (STC-1) to express insulin under the control of the glucose-dependent insulinotropic polypeptide promoter. We screened clones and chose one, Gi-INS-7, based on its high production of insulin. Gi-INS-7 cells expressed glucose transporter 2 (GLUT2) and glucokinase (GK) and secreted insulin in response to elevated glucose levels in vitro. To determine whether Gi-INS-7 cells can control blood glucose levels in diabetic mice, we transplanted these cells under the kidney capsule of streptozotocin (STZ)-induced diabetic mice and found that blood glucose levels became normal within 2 weeks of transplantation. In addition, glucose tolerance tests in mice that became normoglycemic after transplantation with Gi-INS-7 cells showed that exogenous glucose was cleared appropriately. These results suggest that engineered K cells may be promising surrogate β-cells for possible therapeutic use for the treatment of type 1 diabetes.",
author = "Jaeseok Han and Lee, {Hyune Hwan} and Hyokjoon Kwon and Seungjin Shin and Yoon, {Ji Won} and Jun, {Hee Sook}",
year = "2007",
month = "6",
doi = "10.1038/sj.mt.6300117",
language = "English (US)",
volume = "15",
pages = "1195--1202",
journal = "Molecular Therapy",
issn = "1525-0016",
publisher = "Nature Publishing Group",
number = "6",

}

TY - JOUR

T1 - Engineered enteroendocrine cells secrete insulin in response to glucose and reverse hyperglycemia in diabetic mice

AU - Han, Jaeseok

AU - Lee, Hyune Hwan

AU - Kwon, Hyokjoon

AU - Shin, Seungjin

AU - Yoon, Ji Won

AU - Jun, Hee Sook

PY - 2007/6

Y1 - 2007/6

N2 - Type 1 diabetes is a metabolic disorder caused by loss of insulin-producing pancreatic β-cells. Expression of insulin in non-β-cells to create β-cell surrogates has been tried to treat type 1 diabetes. Enteroendocrine K cells have characteristics similar to pancreatic β-cells, such as a glucose-sensing system and insulin-processing proteases. In this study, we genetically engineered an enteroendocrine cell line (STC-1) to express insulin under the control of the glucose-dependent insulinotropic polypeptide promoter. We screened clones and chose one, Gi-INS-7, based on its high production of insulin. Gi-INS-7 cells expressed glucose transporter 2 (GLUT2) and glucokinase (GK) and secreted insulin in response to elevated glucose levels in vitro. To determine whether Gi-INS-7 cells can control blood glucose levels in diabetic mice, we transplanted these cells under the kidney capsule of streptozotocin (STZ)-induced diabetic mice and found that blood glucose levels became normal within 2 weeks of transplantation. In addition, glucose tolerance tests in mice that became normoglycemic after transplantation with Gi-INS-7 cells showed that exogenous glucose was cleared appropriately. These results suggest that engineered K cells may be promising surrogate β-cells for possible therapeutic use for the treatment of type 1 diabetes.

AB - Type 1 diabetes is a metabolic disorder caused by loss of insulin-producing pancreatic β-cells. Expression of insulin in non-β-cells to create β-cell surrogates has been tried to treat type 1 diabetes. Enteroendocrine K cells have characteristics similar to pancreatic β-cells, such as a glucose-sensing system and insulin-processing proteases. In this study, we genetically engineered an enteroendocrine cell line (STC-1) to express insulin under the control of the glucose-dependent insulinotropic polypeptide promoter. We screened clones and chose one, Gi-INS-7, based on its high production of insulin. Gi-INS-7 cells expressed glucose transporter 2 (GLUT2) and glucokinase (GK) and secreted insulin in response to elevated glucose levels in vitro. To determine whether Gi-INS-7 cells can control blood glucose levels in diabetic mice, we transplanted these cells under the kidney capsule of streptozotocin (STZ)-induced diabetic mice and found that blood glucose levels became normal within 2 weeks of transplantation. In addition, glucose tolerance tests in mice that became normoglycemic after transplantation with Gi-INS-7 cells showed that exogenous glucose was cleared appropriately. These results suggest that engineered K cells may be promising surrogate β-cells for possible therapeutic use for the treatment of type 1 diabetes.

UR - http://www.scopus.com/inward/record.url?scp=34249313687&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34249313687&partnerID=8YFLogxK

U2 - 10.1038/sj.mt.6300117

DO - 10.1038/sj.mt.6300117

M3 - Article

C2 - 17299398

AN - SCOPUS:34249313687

VL - 15

SP - 1195

EP - 1202

JO - Molecular Therapy

JF - Molecular Therapy

SN - 1525-0016

IS - 6

ER -